All In Biotech

NDA 203952 · Abbvie

Duopa

Carbidopa, Levodopa · Enteral · Aromatic Amino Acid

Orphan

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 9, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

13,728

9,593 serious, 1,774 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 19, 2026.

DUOPA ® is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. DUOPA is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease ( 1 )

Mechanism: Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats the symptoms of Parkinson's disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DUOPA · CARBIDOPA 4.63MG/ML; LEVODOPA 20MG/ML · SUSPENSION, ENTERAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall1,708
  • death1,028
  • device issue945
  • drug ineffective881
  • parkinson^s disease805
  • device dislocation803
  • hallucination788
  • dyskinesia781
  • urinary tract infection609
  • tremor600
  • asthenia586
  • device occlusion508

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200496
200592
200685
2007107
2008224
2009122
2010150
2011141
2012134
201331
201467
2015314
2016757
2017859
2018973
20191,075
20201,369
20211,444
20221,770
20231,163
20241,060
20251,112
2026583

Recalls

1 FDA enforcement reports for this application.

  • Jan 13, 2017 · Class II · Terminated

    Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Duopa (Carbidopa/Levodopa)

2024 spending

$2.8M

Beneficiaries

53

397 claims

Per beneficiary

$52,563

$2.21 per unit

View as table
YearSpending
2020$1,957,304
2021$2,580,257
2022$3,097,223
2023$2,860,276
2024$2,785,851

Part B: Duopa (Carbidopa/Levodopa) · HCPCS J7340

2024 spending

$52.9M

Beneficiaries

687

7,043 claims

Per beneficiary

$76,958

2024 ASP limit $231.43 per unit

View as table
YearSpending
2020$59,128,735
2021$56,144,672
2022$50,278,780
2023$52,291,876
2024$52,870,158

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.